334 related articles for article (PubMed ID: 25371273)
1. Clinical outcomes of chronic hepatitis C patients related to baseline liver fibrosis stage: a hospital-based linkage study.
Huang Y; de Boer WB; Adams LA; MacQuillan G; Bulsara MK; Jeffrey GP
Intern Med J; 2015 Jan; 45(1):48-54. PubMed ID: 25371273
[TBL] [Abstract][Full Text] [Related]
2. Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome.
Huang Y; de Boer WB; Adams LA; MacQuillan G; Bulsara MK; Jeffrey GP
J Hepatol; 2014 Jul; 61(1):22-7. PubMed ID: 24607623
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.
Berenguer J; Zamora FX; Aldámiz-Echevarría T; Von Wichmann MA; Crespo M; López-Aldeguer J; Carrero A; Montes M; Quereda C; Téllez MJ; Galindo MJ; Sanz J; Santos I; Guardiola JM; Barros C; Ortega E; Pulido F; Rubio R; Mallolas J; Tural C; Jusdado JJ; Pérez G; Díez C; Álvarez-Pellicer J; Esteban H; Bellón JM; González-García J;
Clin Infect Dis; 2015 Mar; 60(6):950-8. PubMed ID: 25422386
[TBL] [Abstract][Full Text] [Related]
4. All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus.
Xu F; Moorman AC; Tong X; Gordon SC; Rupp LB; Lu M; Teshale EH; Spradling PR; Boscarino JA; Trinacty CM; Schmidt MA; Holmberg SD; ; Holmberg SD; Teshale EH; Spradling PR; Moorman AC; Xing J; Tong X; Xu F; Gordon SC; Nerenz DR; Lu M; Lamerato L; Wang Y; Rupp LB; Akkerman N; Oja-Tebbe N; Zhang T; Li J; Sitarik A; Larkin D; Boscarino JA; Daar ZS; Curry PJ; Smith RE; Vijayadeva V; Parker JV; Schmidt MA; Donald JL; Keast EM
Clin Infect Dis; 2016 Feb; 62(3):289-297. PubMed ID: 26417034
[TBL] [Abstract][Full Text] [Related]
5. Prediction of morbidity and mortality in patients with chronic hepatitis C by non-invasive liver fibrosis models.
Chinnaratha MA; Jeffrey GP; MacQuillan G; Rossi E; de Boer BW; Speers DJ; Adams LA
Liver Int; 2014 May; 34(5):720-7. PubMed ID: 24034439
[TBL] [Abstract][Full Text] [Related]
6. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C.
Rutter K; Stättermayer AF; Beinhardt S; Scherzer TM; Steindl-Munda P; Trauner M; Ferenci P; Hofer H
Aliment Pharmacol Ther; 2015 Mar; 41(6):521-31. PubMed ID: 25616017
[TBL] [Abstract][Full Text] [Related]
7. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
8. Prediction of efficacy of interferon treatment of chronic hepatitis C and occurrence of HCC after interferon treatment by a new classification.
Kim KI; Sasase N; Taniguchi M; Mita K; Kim SR; Tanaka K; Hayashi Y
Intervirology; 2005; 48(1):52-8. PubMed ID: 15785090
[TBL] [Abstract][Full Text] [Related]
9. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
10. Efforts to define the natural history of chronic hepatitis C continue.
Ghany MG; Seeff LB
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1190-2. PubMed ID: 17045209
[No Abstract] [Full Text] [Related]
11. Quantitative fibrosis estimation by image analysis predicts development of decompensation, composite events and defines event-free survival in chronic hepatitis B patients.
Bihari C; Rastogi A; Sen B; Bhadoria AS; Maiwall R; Sarin SK
Hum Pathol; 2016 Sep; 55():63-71. PubMed ID: 27189343
[TBL] [Abstract][Full Text] [Related]
12. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C.
Elkrief L; Chouinard P; Bendersky N; Hajage D; Larroque B; Babany G; Kutala B; Francoz C; Boyer N; Moreau R; Durand F; Marcellin P; Rautou PE; Valla D
Hepatology; 2014 Sep; 60(3):823-31. PubMed ID: 24841704
[TBL] [Abstract][Full Text] [Related]
13. SEN virus infection influences the pathological findings in liver but does not affect the incidence of hepatocellular carcinoma in patients with chronic hepatitis C and liver cirrhosis.
Moriyama M; Mikuni M; Matsumura H; Nakamura H; Oshiro S; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Tanaka N; Arakawa Y
Liver Int; 2005 Apr; 25(2):226-35. PubMed ID: 15780043
[TBL] [Abstract][Full Text] [Related]
14. Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection.
Cosconea S; Fontaine H; Méritet JF; Corouge M; Sogni P; Vallet-Pichard A; Mallet V; Legendre C; Pol S
J Hepatol; 2012 Jul; 57(1):55-60. PubMed ID: 22414762
[TBL] [Abstract][Full Text] [Related]
15. [Study on the natural history of chronic hepatitis B].
Wu G; Zhou W; Zhao Y; Guo S; Wang Z; Zou S; Zhang Q; Ren H; Huang A; Zhang D
Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):46-8. PubMed ID: 11856503
[TBL] [Abstract][Full Text] [Related]
16. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
Poynard T; Vergniol J; Ngo Y; Foucher J; Munteanu M; Merrouche W; Colombo M; Thibault V; Schiff E; Brass CA; Albrecht JK; Rudler M; Deckmyn O; Lebray P; Thabut D; Ratziu V; de Ledinghen V; ; ;
J Hepatol; 2014 Apr; 60(4):706-14. PubMed ID: 24291240
[TBL] [Abstract][Full Text] [Related]
17. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.
Tateyama M; Yatsuhashi H; Taura N; Motoyoshi Y; Nagaoka S; Yanagi K; Abiru S; Yano K; Komori A; Migita K; Nakamura M; Nagahama H; Sasaki Y; Miyakawa Y; Ishibashi H
J Gastroenterol; 2011 Jan; 46(1):92-100. PubMed ID: 20711614
[TBL] [Abstract][Full Text] [Related]
18. Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study.
K-Kutala B; Bedossa P; Guedj J; Asselah T; Martinot-Peignoux M; Duval X; Marcellin P
Dig Liver Dis; 2015 Apr; 47(4):296-302. PubMed ID: 25596930
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
Vergniol J; Foucher J; Terrebonne E; Bernard PH; le Bail B; Merrouche W; Couzigou P; de Ledinghen V
Gastroenterology; 2011 Jun; 140(7):1970-9, 1979.e1-3. PubMed ID: 21376047
[TBL] [Abstract][Full Text] [Related]
20. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.
Aleman S; Rahbin N; Weiland O; Davidsdottir L; Hedenstierna M; Rose N; Verbaan H; Stål P; Carlsson T; Norrgren H; Ekbom A; Granath F; Hultcrantz R
Clin Infect Dis; 2013 Jul; 57(2):230-6. PubMed ID: 23616492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
